# Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma

> **NCT03467360** · PHASE1 · RECRUITING · sponsor: **Centre Antoine Lacassagne** · enrollment: 27 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** acetazolamide in combination with platinum and etoposide-based radiochemotherapy
- **DRUG:** acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC

## Key facts

- **NCT ID:** NCT03467360
- **Lead sponsor:** Centre Antoine Lacassagne
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-08-02
- **Primary completion:** 2026-10-27
- **Final completion:** 2027-04-27
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03467360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03467360, "Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03467360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*